Apollomics Inc. filings document the regulatory record of a foreign private issuer developing oncology therapies. Its Form 6-K reports furnish financial-results releases, clinical-development updates for vebreltinib (APL-101), material agreements and license matters, related-party convertible-note financing, collaboration updates, and operational-continuity disclosures.
The filing record also covers governance and control procedures, including director appointments and committee composition, auditor changes, registration-statement incorporation, and litigation-related disclosures. These filings place Apollomics' oncology pipeline, capital structure, public-company governance and risk matters into formal SEC-reporting categories.
Apollomics Inc. director and Chief Operating Officer Chen Yi-Kuei reported that 5,000 restricted stock units vested on September 15, 2026, corresponding to 5,000 Class A ordinary shares. Reported direct holdings after the transaction were 20,100 shares; that amount includes a 100-share adjustment for previously owned shares that had been omitted.
On September 14, 2026, Chen received an option covering 8,000 shares, with a $23.18 exercise price and a September 14, 2036 expiration date. The option vests in two installments, subject to continued service through each vesting date. The reported indirect holding through Maxpro Investment Co., Ltd. was 121,248 Class A ordinary shares.
Apollomics Inc. Chief Financial Officer Peter Kuan-How Lin reported vesting of 10,000 RSUs into 10,000 Class A ordinary shares on September 15, 2026; the derivative transaction row reports 10,000 RSUs following the transaction. On that date, 3,416 shares were delivered or withheld for payment of exercise price or tax liability at a reported $24.02 per share. Lin also received a 6,000-option grant on September 14, 2026, with a $23.18 exercise price and a September 14, 2036 expiration date. Fifty percent vests on March 14, 2027, and the remaining fifty percent on September 14, 2027, subject to continued service. The amendment corrects the option expiration date. No Rule 10b5-1 plan is reported.
Apollomics Inc. director Yen Hung Hsien’s transactions include 500 restricted stock units that vested on September 15, 2026, with 500 Class A ordinary shares acquired. On September 14, 2026, Hsien was granted 2,000 stock options with a $23.18 exercise price and a September 14, 2036 expiration date; the amendment corrects the option’s expiration date. The options vest 50% on March 14, 2027, and 50% on September 14, 2027, subject to continued service through each date.
Apollomics Inc. (APLM) reported insider equity transactions by Chief Financial Officer and director Peter Kuan-How Lin. On September 15, 2026, 10,000 Restricted Stock Units previously reported vested and were converted into 10,000 Class A Ordinary Shares, and 3,416 of those shares were delivered or withheld to cover exercise price or tax liability.
On September 14, 2026, Lin also received a grant of 6,000 stock options under the Apollomics Inc. 2023 Incentive Award Plan at an exercise price of $23.18 per share. These options vest over one year, with 50% vesting on March 14, 2027 and the remaining 50% on September 14, 2027, subject to continued service. No Rule 10b5-1 trading plan is reported for these transactions.
Apollomics Inc. (APLM) director Chen Hong-Jung reported equity compensation activity and a vesting-related share issuance. On September 15, 2026, 500 restricted stock units vested and were converted into 500 Class A Ordinary Shares, leaving 4,120 shares held directly. On September 14, 2026, Chen received a grant of stock options for 2,000 Class A Ordinary Shares at an exercise price of $23.18 per share, expiring September 14, 2036, vesting in two equal tranches on March 14, 2027 and September 14, 2027, subject to continued service. No Rule 10b5-1 trading plan is reported.
Apollomics Inc. (APLM) reported that director and Chief Operating Officer Chen Yi-Kuei had 5,000 restricted stock units vest on September 15, 2026, converting into 5,000 Class A Ordinary Shares held directly, bringing his direct holdings to 20,100 shares. On September 14, 2026 he was also granted a stock option for 8,000 shares at $23.18 per share under the 2023 Incentive Award Plan, vesting in two equal installments in 2027. In addition, 121,248 Class A Ordinary Shares are reported as held indirectly through Maxpro Investment Co., Ltd., with beneficial ownership disclaimed except to the extent of his pecuniary interest. No Rule 10b5-1 trading plan is reported.
Apollomics Inc. (APLM) director Tsai Hsien-Shu reported equity compensation activity. On September 15, 2026, 500 Restricted Stock Units vested and were settled into 500 Class A Ordinary Shares, bringing the director’s direct holdings to 2,000 Class A Ordinary Shares. On September 14, 2026, the director also received a stock option grant for 2,000 Class A Ordinary Shares at an exercise price of $23.18 per share, expiring September 14, 2036, under the Apollomics Inc. 2023 Incentive Award Plan. The option vests 50% on March 14, 2027 and 50% on September 14, 2027, subject to continued service. No Rule 10b5-1 trading plan is reported.
Apollomics Inc. (APLM) director Yen Hung Hsien reported equity compensation activity. On September 15, 2026, 500 Restricted Stock Units covering 500 Class A Ordinary Shares were exercised into 500 directly owned Class A Ordinary Shares. On September 14, 2026, the director received a grant of 2,000 stock options at an exercise price of $23.18 per share under the Apollomics Inc. 2023 Incentive Award Plan, vesting 50% on March 14, 2027 and 50% on September 14, 2027, subject to continued service.
Apollomics Inc. (APLM) reported that director Huang Ya-Chi received a grant of 2,000 stock options on September 14, 2026 under the Apollomics Inc. 2023 Incentive Award Plan, with an exercise price of $23.18 per Class A ordinary share and an expiration date of September 14, 2036.
According to the grant terms, 50% of the option vests and becomes exercisable on March 14, 2027 and the remaining 50% vests on September 14, 2027, subject to Huang’s continued service. Following this grant, Huang holds 2,000 stock options directly, and no Rule 10b5-1 trading plan is reported.
Apollomics Inc. (APLM) reported that Chief Executive Officer and director Hung-Wen Chen had 5,000 Restricted Stock Units vest on September 15, 2026, converting into 5,000 Class A Ordinary Shares and bringing his directly held Class A shares to 423,334. On September 14, 2026, he also received a grant of 8,000 stock options with an exercise price of $23.18 per share, expiring on September 14, 2036, vesting in two equal installments on March 14, 2027 and September 14, 2027, subject to continued service. In addition, 1,029,695 Class A Ordinary Shares are held indirectly through King Regent Management Limited, over which he has voting and dispositive power but disclaims beneficial ownership except to the extent of his pecuniary interest.